Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A3H2101
Wed, 17.04.2024
aap Implantate AG
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014
aap postpones publication of the consolidated financial statements 2023 due to staff shortages
Berlin, 17. April 2024, time: 6:25 pm
aap Implantate AG ("aap" or "Company") postpones the publication of the annual financial report for the financial [ … ]
Mon, 18.03.2024
aap Implantate AG
Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
The Management Board of aap Implantate AG ("Company") resolved today, with the approval of the Supervisory Board, to increase the Company's share capital against cash contributions by issuing new no-par value bearer shares with a pro rata amount of the share c [ … ]
Tue, 05.03.2024
aap Implantate AG
aap Implantate AG ("aap" or "Company") proposes to the creditors of the mandatory convertible bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH) traded on the open market of the Frankfurt Stock Exchange to resolve on an amendment to the terms and conditions of the bond by way of a vote without a meeting of bondholders. The amendment to the terms and [ … ]
Thu, 21.12.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or "Company") adjusts the forecast for sales and EBITDA for the financial year 2023. In addition, the Management Board today approved a package of measures for extensive staff reductions and further cost reductions.
The Management Board expects sales of EUR 11.2 million to EUR 11.8 million for the [ … ]
Wed, 04.10.2023
aap Implantate AG
aap Implantate AG ("aap" or the "Company") today completed the placement of the mandatory convertible bond 2023/2028, which the Company's Management Board resolved to issue with the approval of the Supervisory Board on September 8, 2023.
The issue met with a positive response from shareholders and new investors of aap in a capital market environmen [ … ]
Fri, 08.09.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") resolved today, with the approval of the Supervisory Board on the same day, to make use of the authorization granted by the Annual General Meeting on June 21, 2022 to issue convertible bonds and to issue a non-subordinated and unsecured mandatory convertible bond 2023/2028 in the to [ … ]
Fri, 21.07.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding
Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items [ … ]
Fri, 21.07.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding
Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items [ … ]
Tue, 13.06.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the consent of the Supervisory Board, to propose to the Company's Annual General Meeting to be convened on July 25, 2023, to resolve on the following capital measures:
Reduction of the share capital of the Company from currently EUR 8,955,849.00 by EUR 6,716,88 [ … ]
Tue, 13.06.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the consent of the Supervisory Board, to propose to the Company's Annual General Meeting to be convened on July 25, 2023, to resolve on the following capital measures:
Reduction of the share capital of the Company from currently EUR 8,955,849.00 by EUR 6,716,88 [ … ]